Affinity Asset Advisors »

Engene Therapeutics shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Engene Therapeutics (ENGN) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Engene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Engene Therapeutics held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Engene Therapeutics by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.0M 600k 1.73

More positions owned by Affinity Asset Advisors

Roivant Sciences SHS (ROIV)
Apogee Therapeutics (APGE)
Spyre Therapeutics Com New (SYRE)
Xenon Pharmaceuticals (XENE)
Erasca (ERAS)
Alkermes SHS (ALKS)
Insmed Com Par $.01 (INSM)
Moderna Put Option (MRNA)
Praxis Precision Medicines I Com New (PRAX)
Oruka Therapeutics (ORKA)
Anaptysbio Inc Common (ANAB)
Avalo Therapeutics Com New (AVTX)
Cytokinetics Com New (CYTK)
Revolution Medicines (RVMD)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Affinity Asset Advisors

Top funds holding Engene Therapeutics

Perceptive Advisors
Nextech Invest
ADAR1 Capital Management
Balyasny Asset Management
Millennium Management
Renaissance Technologies
Citadel Advisors
Affinity Asset Advisors
Jane Street
Rangeley Capital
Barclays
Elmind Capital
Two Sigma Investments
Marquette Asset Management
Jain Global

View all funds holding Engene Therapeutics